SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after its Q4 earnings report, which, despite solid subscriber growth and ad revenue, prompted a significant stock decline due to conservative Q1 guidance and investor concerns over the proposed Warner Bros. Discovery acquisition. The community is sharply divided; bulls view the deep pullback as an oversold opportunity given strong long-term fundamentals and content potential, while bears focus on the acquisition's cost, debt implications, and paused share buybacks as potential headwinds for future profitability.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending as Donald Trump's remarks at the World Economic Forum captivate audiences, with community attention centered on his controversial proposals for tariffs and persistent calls to acquire Greenland. These statements are fueling polarized debates regarding their potential impact on international relations and market stability, alongside widespread commentary on his public speaking style.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, was awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development has ignited widespread community discussion, with many highlighting the stock's low share float and speculating about a potential short squeeze, drawing parallels to other recent volatile small-cap movements. Community members are actively debating the contract's impact on PAVmed's valuation, especially given its significant ownership stake in Lucid.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively trending as market participants analyze former President Trump's speech at the World Economic Forum in Davos. His remarks, particularly those concerning Greenland and the broader economic outlook, are sparking intense debate within the community. Discussion centers on whether his bullish pronouncements or controversial international rhetoric will ultimately dictate market sentiment amid geopolitical tensions.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing heightened investor attention and bullish momentum as multiple analyst upgrades and anticipation of its upcoming earnings report fuel a narrative of a strong turnaround. The community is actively discussing its resilience and upward trajectory, particularly given its performance on down market days, with many highlighting its strategic position in AI and domestic manufacturing capabilities amidst robust demand.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is a major discussion point after announcing it met revised 2025 production targets and increased vehicle deliveries, boosted by the Gravity SUV, alongside news of a robotaxi alliance with Uber and Nuro. While some investors see this as a sign of operational progress, community sentiment remains divided, with concerns over long-term profitability, cash burn, and leadership driving ongoing, intense debate within the challenging EV market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a top trending stock after securing a $2.05 million AI licensing partnership in Africa, which includes a pilot program with Nelson Mandela University. The community is intensely focused on the stock's notably low float and high short interest, driving widespread discussion about a potential squeeze. While many anticipate further upside, others express caution, debating the valuation in light of the deal size and raising concerns about potential volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing intense community discussion, fueled by recent high-grade silver drill results and a broadly bullish sentiment across precious metals markets. Investors are actively debating the company's valuation, weighing its significant resource potential and strategic investor interest against its current pre-production status and capital requirements.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is actively discussed following positive FDA guidance that sets a path for expanded use of its ANKTIVA treatment for bladder cancer, with the community noting no new trials are required and a resubmission timeline established. Investors are highly engaged, anticipating further global approvals
including for lung cancer
and future catalysts like AI-driven manufacturing, fueling strong conviction amidst persistent short interest.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amidst a recent bondholder lawsuit claiming losses due to undisclosed debt related to its AI infrastructure investments, sparking intense community debate about its financial health and market volatility. While many express concern over the substantial debt and recent price declines, others remain optimistic, highlighting an impending TikTok deal and a significant backlog of cloud and AI contracts as key drivers for long-term growth in the evolving tech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pacific Heights Asset Management LLC Raises Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Pacific Heights Asset Management LLC increased its stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 52.2% in the third quarter, according to its most recent...

Short Interest in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Grows By 23.7%

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totaling...

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Consensus Rating of "Moderate Buy" by Analysts

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has earned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are currently covering the stock...

SG Americas Securities LLC Has $1.11 Million Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

SG Americas Securities LLC raised its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 106.4% during the 3rd quarter, according to its most recent filing with the...

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Here's What Happened...

LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling

Eli Lilly stock declines after the FDA reportedly delays a decision on its obesity pill orforglipron, pushing the timeline to April and giving NVO more time.

Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its experimental pill to market.read more...

How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?

Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.

<ul class="summary-bullets"><li>Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears.</li><li>Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.</li><li>Novo recently lost out to Pfizer in the bidding war for smaller obesity drugmaker Metsera but completed its acquisition of Akero therapeutics in December.</li></ul>Shares of obesity drugmaker Viking Therapeutics (VKTX) rallied 17% on Wednesday after Denmark-based Wegovy producer Novo Nordisk (NVO) said it is on the lookout for merger and acquisition deals to boost its drug portfolio.Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets, and companies that are complementary to its portfolio.Other obesity drug manufacturing stocks also rallied at the time of writing, including Terns Pharmaceuticals (TERN), and Structure Therapeutics (GPCR). <a href="https://stocktwits.com/symbol/TERN">TERN shares</a> rose 10% at the time of writing while <a href="https://stocktwits.com/symbol/GPCR">GPCR stock</a> rose 6%.<h2 class="st-heading-2">Novo’s Recent Acquisition Attempts</h2>Doustdar said that the company can afford any amount for an asset, provided it is worth it. Talking about Novo Nordisk’s recent $10 billion bid to acquire smaller obesity drug maker Metsera, the CEO said, “We stopped at $10 billion in Metsera because to us, it was not worth a penny more.” Novo <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-ceo-eyes-big-push-towards-obesity-drug-development-in-2026/cmUafq6R4ED">lost out to Pfizer</a> in the bidding war.However, in December, Novo completed its acquisition of Akero Therapeutics for up to $5.2 billion in a bid to gain access to its experimental drug Efruxifermin, being developed for the treatment of compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH).<h2 class="st-heading-2">Viking’s Obesity Pipeline</h2>The subcutaneous formulation of Viking Therapeutics' lead candidate VK2735 is currently in late-stage trials for obesity. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The company is also studying a tablet formulation of the drug.Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is broader than it appears."I think the interest is probably broader than is visible. I think that there are more parties sort of circling around the space and very intrigued," Lian said while adding that he thinks there is a "fair amount of interest” across the industry.Lian also said in October that the company is “certainly receptive” to outside interest in its obesity program.“...having a larger party involved would be, you know, very helpful in driving the program through commercialization,” he said. “That said, I don't think it's mandatory. I think it's probably a preference, but it's not mandatory. We're prepared to go alone, but we're also prepared to engage with anybody who's interested.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VKTX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that Novo might buy Viking for about $10 billion, representing massive upside from its current near $4 billion market cap.<stembedurl>https://www.stocktwits.com/CPA_/message/641819411</stembedurl><a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-bear-says-new-fsd-subscription-model-proves-the-tech-is-not-an-asset/cmULNffR4eU">Tesla Bear Says New FSD Subscription Model Proves The Tech Is Not An Asset: Retail Echoes Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 

Equity

Novo CEO Mike Doustdar said on Tuesday during the annual JP Morgan Healthcare conference that the company will continue searching for molecules, assets and companies that are complementary to its portfolio. 


VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug

Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$90.39
Prev Close	$91.02
Open	$93.22
Dividend Yield	0.00%
50-Day Moving Average	$54.97
Beta	1.01
Avg. Volume	2.27M
PE Ratio	-24.92

52-Week High	$94.90
52-Week Low	$13.22
Market Capitalization	$6.43B
EPS (Annual)	-$2.33
Price to Book	7.17
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GPCR
Structure Therapeutics Inc - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GPCR News

GPCRStructure Therapeutics Inc - ADR